| Objective:In this study,we observed the effect of Heart Failure Formula 2 on cardiac function,clinical symptoms and quality of life in patients with chronic heart failure.We also detected the expression levels of gene-21 and TGF-beta-1 in patients with chronic heart failure,explored the effect of Heart Failure Formula 2 on myocardial fibrosis in patients with NYHA cardiac function grade II-IV,and explored its possible mechanism from a targeted point of view.Method:In this study,44 patients with NYHA grade II-III chronic heart failure admitted to the outpatient and ward of Changzhou Hospital of Traditional Chinese Medicine from 01.2018 to 01.2019 were divided into two groups according to the odd and even number of patients’case numbers.The odd and even number of patients’ case numbers were the control group and the even number was the experimental group.The age ranged from 18 to 80 years in both groups.In the experiment,23 patients in the control group were given standard anti-heart failure treatment with Western medicine.The 21 patients in the treatment group were treated with Heart Failure Foinula 2 on the basis of the standard anti-heart failure treatment of Western medicine.Formula:Chinese herbal decoction.Direction:Take 150 ml orally twice a day(half an hour after meals).The course of treatment was 30 days.The TCM syndrome score,Minnesota quality of life score,left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVEDS),left ventricular ejection fraction(LVEF),serum NT-proBNP,NYHA cardiac function classification,plasma TGF-beta 1 and plasma microRNA-21 levels were compared before and after one month.Results:1.NTpro-BNP in both groups decreased significantly after treatment,with significant difference compare d with before treatment(P<0.05).The difference of serum NT-proBNP concentration before and after treatment in the experimental group was greater than that in the control group,with statistical significance(P<0.05).2.There was no significant difference between the two groups in cardiac hyperactivity index(LVEF,LVEDD,LVEDS)before and after treatment(P>0.05).3.There was significant difference in NYHA cardiac function classification between the two groups before and after treatment(P<0.05).There was no significant difference in NYHA cardiac function classification between the two groups before and after treatment(P>0.05).There was no significant difference in the curative effect of NYHA cardiac function between the two groups(P>0.05).4.There were significant differences in TCM syndrome scores between the two groups before and after treatment(P<0.05).The difference of TCM syndrome scores between the experimental group before and after treatment was larger than that of the control group(P<0.05),and the therapeutic effect of TCM syndrome in the experimental group was better than that of the control group(P<0.05).5.The difference of Minnesota quality of life score between the two groups before and after treatment was statistically significant(P<0.05).The difference of Minnesota quality of life score between the experimental group before and after treatment was greater than that of the control group,and the difference was statistically significant(P<0.05).6.The plasma levels of TGF-beta 1 in both groups decreased after treatment,and there was a significant dif’ference between the two groups before and after treatment(P<0.05).The difference of plasma levels of TGF-beta 1 in the experimental group was larger than that in the control group before and after treatment(P>0.05).7.The concentration of plasma microRNA-21 in the experimental group decreased after treatment,with significant difference compared with that before treatment(P<0.05).The concentration of plasma microRNA-21 in the control group did not decrease significantly after treatment,and there was no significant difference compared with that before treatment(P>0.05).Conclusion:Compared with the control group,the experimental group further reduced the scores of TCM syndromes and quality of life in patients with chronic heart failure,and could further reduce the level of NTpro-BNP in serum and the expression of microRNA21 in plasma.There was no significant improvement in ejection fraction and left ventricular diameter between the two groups.Both groups could significantly reduce plasma TGF-beta 1 concentration,suggesting that the decrease rate of TGF-beta 1 concentration in the experimental group was slightly higher than that in the control group.These results suggest that Heart Failure Formula 2 can further improve the symptoms and quality of life of patients and inhibit myocardial fibrosis on the basis of Western medicine treatment.It may be speculated that the mechanism may be related to the transforming growth factor-beta signaling pathway regulated by microRNA21. |
PDF Full Text Request